What is United Therapeutics Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. United Therapeutics's annualizedGross Profit for the quarter that ended in Mar. 2025 was $2,808 Mil.
United Therapeutics's average Total Assets over the quarter that ended in Mar. 2025 was $7,554 Mil. Therefore, United Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 37.17%.
United Therapeutics Gross-Profit-to-Asset % Historical Data
The historical data trend for United Therapeutics's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of United Therapeutics's Gross-Profit-to-Asset %
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2025) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
United Therapeutics Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of United Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UTHR has been successfully added to your 